secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apimeds Pharmaceuticals US, Inc. (APUS)
CIK:        0001894525
Form:       8-K/A
Filed at:   2026-02-17T23:59:59+00:00
Accession:  0001213900-26-017323
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 9.01, 2.01
LLM model:  deepseek-v4-flash:cloud@v2

MindWave posts six-month net loss $6.6M on zero revenue; digital assets $132.3M
-------------------------------------------------------------------------------

- Net loss $6.6M for six months ended Sep 30, 2025 vs net income $57.8M in prior year period.
- No revenue from operations; digital assets at fair value $132.3M (incl. restricted).
- Total equity $132.3M, zero liabilities; unrealized loss $9.1M from digital asset remeasurement.
- Financials filed as Exhibit 99.1 for reverse merger with Apimeds (APUS) previously reported.
- Company holds crypto tokens ($NILA) and generates gains mainly from sale of digital assets.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1894525/000121390026017323/0001213900-26-017323-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1894525/000121390026017323/ea0277267-8ka2_api.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-017323

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer